Efficacy of Tramadol in Treatment of Pain in Fibromyalgia

Russell, Jon I.; Kamin, Marc; Bennett, Robert M.; Schnitzer, Thomas J.; Green, Jerry A.; Katz, Warren A.

doi:10.1097/00124743-200010000-00004

Cited by 127 publications

(94 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 One of the virtues of the design is that exposure of patients to placebo can be short, yet it still allows for an assessment of long-term efficacy. In this setting, the demonstration of efficacy depends upon the occurrence of treatment failure in significantly more subjects exposed to placebo compared with the active treatment.…”

Section: Discussionmentioning

confidence: 99%

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

et al. 2011

View full text Add to dashboard Cite

Background: Open-label studies are not ideal for providing robust evidence for long-term maintenance of efficacy of medicines, especially where medicines provide symptom relief and where long-term use of a placebo may be problematic and not ethical. Objective: To evaluate the maintenance of efficacy of Sativex in subjects who have gained long-term symptomatic relief of spasticity in multiple sclerosis (MS), and to assess the impact of sudden medicine withdrawal. Methods: An enriched enrolment randomized withdrawal study design was used. Eligible subjects with ongoing benefit from Sativex for at least 12 weeks entered this 5-week placebo-controlled, parallel-group, randomized withdrawal study. Each subjects’ previous effective and tolerated dose was continued. Results: A total of 18 subjects per group were enrolled. Demographics showed a mean duration of MS of 16.4 years, spasticity 12.7 years, mean duration of Sativex use of 3.6 years (median 3.4 years) and a mean daily dose of 8.25 sprays. Primary outcome of time to treatment failure was significantly in favour of Sativex ( p = 0.013). Secondary endpoints showed significant changes in the Carer and Subject’s Global Impression of Change scales in favour of Sativex. Conclusions: Maintenance of Sativex efficacy in long-term symptomatic improvement of spasticity to a group of subjects with MS has been confirmed using this study design.

show abstract

Section: Discussionmentioning

confidence: 99%

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Other drugs, such as the dualreuptake inhibitor/atypical opioid tramadol, 77 the older SSRIs such as fluoxetine, 40 GHB, 78 and the dopamine agonist pramipexole 79 appear to be beneficial in fibromyalgia despite less compelling evidence. Tramadol seems to be safe and effective for most patients as both monotherapy 77 and in combination with acetaminophen.…”

Section: Possibly Effective Treatment Optionsmentioning

confidence: 99%

“…Tramadol seems to be safe and effective for most patients as both monotherapy 77 and in combination with acetaminophen. 80 Dr. Clauw mentioned that the side effect profile for combined tramadol/ acetaminophen includes nausea, dizziness, headache, pruritus, constipation, and somnolence, which is similar to that of tramadol as monotherapy.…”

Section: Possibly Effective Treatment Optionsmentioning

confidence: 99%

Understanding Fibromyalgia and Its Related Disorders

Goldenberg¹

2008

Prim. Care Companion J. Clin. Psychiatry

View full text Add to dashboard Cite

“…In addition to amitriptyline 18 and duloxetine, 19 other antidepressants, such as fl uoxetine 20 and milnacipran, 21,22 and several other drugs, such as ciclobenzaprine, 23,24 gabapentin, 25 pregabalin, 26,27 and tramadol, 28,29 have been tested in controlled studies and have shown promising responses in relieving fi bromyalgia symptoms. Although all the above-cited drugs have been studied and have been part of these patients' pharmacological therapy, currently, duloxetine and pregabalin are the only drugs approved by the Food and Drug Administration (FDA) for treating fi bromyalgia.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Uso da terapia não farmacológica, medicina alternativa e complementar na fibromialgia

Braz¹,

Paula

Diniz³

et al. 2011

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Fibromyalgia is a chronic painful syndrome that affects up to 5% of the world population. It is associated with sleep and mood disorders, fatigue, and functional disability. Its pathogenesis involves a disorder of the central modulation of pain, impairment of the descending inhibitory system, and hyperactivity of substance P. Because of the extensive symptomatology of patients with fi bromyalgia and its multifactorial pathogenesis, its ideal treatment requires a multidisciplinary approach including the association of pharmacological and non-pharmacological therapies. The pharmacological therapy currently recommended for the syndrome includes antidepressants, calcium-channel modulators, muscle relaxants, and analgesics. In most cases, the non-pharmacological treatment consists of patient education, supervised aerobic physical activity, and cognitive-behavioral therapy. However, many patients do not respond satisfactorily, or have side effects associated with the long-term use of drugs, in addition to reporting diffi culties in adhering to a therapy based on exercises and physical medicine. Thus, physicians and patients are increasingly interested in an alternative and complementary therapy for fi bromyalgia. This review approaches the different therapeutic modalities used in fi bromyalgia, emphasizing the evidence of non-pharmacological therapy and use of alternative and complementary medicine for these patients.

show abstract

Efficacy of Tramadol in Treatment of Pain in Fibromyalgia

Cited by 127 publications

References 0 publications

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

Understanding Fibromyalgia and Its Related Disorders

Uso da terapia não farmacológica, medicina alternativa e complementar na fibromialgia

Contact Info

Product

Resources

About